Systemic CD4+ T cell phenotype and activation status in intermediate uveitis

British Journal of Ophthalmology

Volumn 88, Issue 3, 2004, Pages 412-416

  Murphy, C C ^b   Duncan, L ^c   Forrester, J V ^c   Dick, A D ^a,b  

^a BRISTOL EYE HOSPITAL   (United Kingdom)

^b UNIVERSITY OF BRISTOL   (United Kingdom)

^c UNIVERSITY OF ABERDEEN   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; CD69 ANTIGEN; CHEMOKINE RECEPTOR; CHEMOKINE RECEPTOR CCR4; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CXCR3; CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 5; TUMOR NECROSIS FACTOR ALPHA;

ADOLESCENT; ADULT; ARTICLE; CELL ACTIVATION; CELL CULTURE; CELL STIMULATION; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE COURSE; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; INTERMETHOD COMPARISON; MALE; MEDICAL ASSESSMENT; PATIENT SELECTION; PERIPHERAL LYMPHOCYTE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SARCOIDOSIS; STATISTICAL SIGNIFICANCE; SUPERNATANT; T LYMPHOCYTE; UVEITIS;

ADOLESCENT; ADULT; ANTIGENS, CD; ANTIGENS, DIFFERENTIATION, T-LYMPHOCYTE; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; FEMALE; HUMANS; LYMPHOCYTE ACTIVATION; MALE; MIDDLE AGED; PHENOTYPE; RECEPTORS, CCR5; RECEPTORS, CHEMOKINE; TH1 CELLS; TH2 CELLS; TUMOR NECROSIS FACTOR-ALPHA; UVEITIS;

EID: 1542511822     PISSN: 00071161     EISSN: None     Source Type: Journal    
DOI: 10.1136/bjo.2003.028506     Document Type: Article

References (31)

1. Caspi RR, Sun B, Agarwal RK, et al. T cell mechanisms in experimental autoimmune uveoretinitis: susceptibility is a function of the cytokine response profile. Eye 1997;11:209-12.
2. Sugi-Ikai N, Nakazawa M, Nakamura S, et al. Increased frequencies of interleukin-2 and interferon-gamma-producing T cells in patients with active Behçet's disease. Invest Ophthalmol Vis Sci 1998;39:996-1004.
3. Lacomba MS, Martin CM, Chamond RR, et al. Aqueous and serum interferon gamma, interleukin (IL) 2, IL-4, and IL-10 in patients with uveitis. Arch Ophthalmol 2000;118:768-72.
4. Palexas GN, Sussman G, Welsh NH. Ocular and systemic determination of IL-1 beta and tumour necrosis factor in a patient with ocular inflammation. Scand J Immunol Suppl 1992;11:173-5.
5. Dick AD, McMenamin PG, Korner H, et al. Inhibition of tumor necrosis factor activity minimizes target organ damage in experimental autoimmune uveoretinitis despite quantitatively normal activated T cell traffic to the retina. Eur J Immunol 1996;26:1018-25.
6. Dick AD, Duncan L, Hale G, et al. Neutralizing TNF-alpha activity modulates T-cell phenotype and function in experimental autoimmune uveoretinitis. J Autoimmun 1998;11:255-64.
7. Santos Lacomba M, Marcos Martin C, Gallardo Galera JM, et al. Aqueous humor and serum tumor necrosis factor-alpha in clinical uveitis. Ophthalmic Res 2001;33:251-5.
8. Cope AP. Regulation of autoimmunity by proinflammatory cytokines. Curr Opin Immunol 1998;10:669-76.
9. Sharief MK, Hentges R. Association between tumor necrosis factor-alpha and disease progression in patients with multiple sclerosis. N Engl J Med 1991;325:467-72.
10. Davis JL, Solomon D, Nussenblatt RB, et al. Immunocytochemical staining of vitreous cells. Indications, techniques, and results. Ophthalmology 1992;99:250-6.
11. Wetzig RP, Chan CC, Nussenblatt RB, et al. Clinical and immunopathological studies of pars planitis in a family. Br J Ophthalmol 1988;72:5-10.
12. El-Shabrawi Y, Livir-Rallatos C, Christen W, et al. High levels of interleukin-12 in the aqueous humor and vitreous of patients with uveitis. Ophthalmology 1998;105:1659-63.
13. Bonecchi R, Bianchi G, Bordignon PP, et al. Differential expression of chemokine receptors and chemotactic responsiveness of type 1 T helper cells (Th1s) and Th2s. J Exp Med 1998;187:129-34.
14. Benezra D FJ, Nussenblatt RB, Tabbara K, et al. Uveitis scoring system. Berlin: Springer-Verlag, 1991.
15. Cook EB, Stahl JL, Lowe L, et al. Simultaneous measurement of six cytokines in a single sample of human tears using microparticle-based flow cytometry: allergics vs. non-allergics. J Immunol Methods 2001;254:109-18.
16. Tervo T, van Setten GB, Hovi M, et al. C-reactive protein serum levels in patients with ocular disease. Acta Ophthalmol (Copenh) 1994;72:110-13.
17. Testi R, D'Ambrosio D, De Maria R, et al. The CD69 receptor: a multipurpose cell-surface trigger for hematopoietic cells. Immunol Today 1994;15:479-83.
18. Kilmartin DJ, Fletcher ZJ, Almeida JA, et al. CD69 expression on peripheral CD4+ T cells parallels disease activity and is reduced by mycophenolate mofetil therapy in uveitis. Invest Ophthalmol Vis Sci 2001;42:1285-92.
19. Klok AM, Luyendijk L, Zaal MJ, et al. Elevated serum IL-8 levels are associated with disease activity in idiopathic intermediate uveitis. Br J Ophthalmol 1998;82:871-4.
20. Klok AM, Luyendijk L, Zaal MJ, et al. Soluble ICAM-1 serum levels in patients with intermediate uveitis. Br J Ophthalmol 1999;83:847-51.
21. Dick AD, Cheng YF, Purdie AT, et al. Immunocytochemical analysis of bload lymphocytes in uveitis. Eye 1992;6:643-7.
22. Deschenes J, Char DH, Kaleta S. Activated T lymphocytes in uveitis. Br J Ophthalmol 1988;72:83-7.
23. Feron EJ, Calder VL, Lightman SL. Oligoclonal activation of CD4+ T lymphocytes in posterior uveitis. Clin Exp Immunol 1995;99:412-18.
24. Reiff A, Takei S, Sadeghi S, et al. Etanercept therapy in children with treatment-resistant uveitis. Arthritis Rheum 2001;44:1411-15.
25. Lipsky PE, van der Heijde DM, St Clair EW, et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med 2000;343:1594-602.
26. Targan SR, Hanauer SB, van Deventer SJ, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med 1997;337:1029-35.
27. Sfikakis PP, Theodossiadis PG, Katsiari CG, et al. Effect of infliximab on sight-threatening ponuveitis in Behçet's disease. Lancet 2001;358:295-6.
28. Kroemer G, Hirsch F, Gonzalez-Garcia A, et al. Differential involvement of Th1 and Th2 cytokines in autoimmune diseases. Autoimmunity 1996;24:25-33.
29. Barton K, McLauchlan MT, Calder VL, et al. The kinetics of cytokine mRNA expression in the retina during experimental autoimmune uveoretinitis. Cell Immunol 1995;164:133-40.
30. Inui N, Chida K, Suda T, et al. TH1/TH2 and TC1/TC2 profiles in peripheral blood and bronchoalveolar lavage fluid cells in pulmonary sarcoidosis. J Allergy Clin Immunol 2001;107:337-44.
31. Mollers M, Aries SP, Dromann D, et al. Intracellular cytokine repertoire in different T cell subsets from patients with sarcoidosis. Thorax 2001;56:487-93.